News | October 09, 2022
Pfizer acquires Global Blood Therapeutics
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The company increases its efficiency and is able to face the growing demand for its services.
Study achieves primary endpoint of radiographic progression-free survival
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
This win is on the back of a prestigious order from Reliance Life Sciences
Both products are broad-spectrum, foliar insecticides used across wide range of crops
The product will be manufactured at Lupin's facility in Nagpur, India.
The inspection concluded with no observation (FDA-483) issued.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Subscribe To Our Newsletter & Stay Updated
